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dimensional model of the instrument with group type (exercise or control) as the 
criterion variable to assess model invariance. RESULTS: A total of 89 participants 
completed the trial of which 48 were in the exercise group. Evidence of variation in 
the factorial structure of the EPDS between groups was found suggesting the invari-
ance assumption may not be supported. CONCLUSIONS: The assumption that the 
outcome measure (EPDS) is invariant between groups within an RCT was not sup-
ported. Further investigation is required to evaluate the impact of outcome measure 
variance on treatment effects in clinical trials where self-report measure data is used 
as primary and/or secondary outcomes.
INDIVIDUAL’S HEALTH – Cost Studies
PIH9
TRENDS IN IUD INSERTIONS AND RELATED MEDICAL EXPENDITURE 
IN THE UNITED STATES: THE POPULATION WITH EMPLOYER-
SPONSORED INSURANCE
Xu X, Macaluso M, Ouyang L, Grosse S
Centers for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: The prevalence of intrauterine device (IUD) use is low among women 
of reproductive age in the United States. The objective of this study was to examine 
the trend in IUD insertions and related medical expenditures between 2002 and 2007 
in a population of women covered by employer-sponsored health insurance (ESI). 
METHODS: We conducted a population-based study using the MarketScan Com-
mercial Claims and Encounter Enrolled Population database. We identiﬁed women, 
15–49 years old who ﬁled a claim for the insertion of an IUD or IUS (the Levonorg-
estrel-releasing IUD) between January 1, 2002 and December 31, 2007. We adopted 
the MarketScan national weights in order to generate nationally representative esti-
mates. RESULTS: The number of new IUD/IUS patients in the ESI-covered population 
doubled, from 70,851 (2/1,000 eligible women) in 2002 to 154,366 (8/1,000) in 2007. 
Meanwhile, the market share of the IUS increased from 35% to 80% of all IUD 
insertions. The mean copayment for IUD (IUS) devices decreased from $13.0 ($14.6) 
in 2002 to $3.5 ($3.6) in 2007 after adjusting for inﬂation (in 2007 dollars), and the 
percent of patients with zero copayment for the device and for the insertion procedure 
increased from 65% to more than 80% and form 58% to 73%, respectively. The 
average net reimbursement for the IUD increased 17.5% between 2002 and 2007, 
from $311.92 to $366.64, while that for the IUS increased 7.5%, from $405.36 to 
$435.49. CONCLUSIONS: The increase in medical expenditures associated with IUD/
IUS insertions from 2002 to 2007 was driven by the growth in IUS insertions. IUDs 
have lower contraceptive failure rates than other reversible contraceptive methods, 
and higher rates of IUD use should lead to fewer unwanted pregnancies. Additional 
research is needed to understand whether the recent growth in IUS insertions is related 
to changing provider attitudes and more favorable insurance coverage.
PIH10
TREATMENT PATTERNS AND ECONOMIC BURDEN OF UTERINE 
FIBROIDS IN A UNITED STATES MANAGED CARE DATABASE
Bapat B1, Davis K1, Bell KF2, Deal LS2, Talbird SE3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Pﬁzer, Collegeville, PA, USA, 3RTI 
Health Solutions, RTP, NC, USA
OBJECTIVES: To document surgical treatment patterns of uterine ﬁbroid (UF) 
patients and total all-cause medical costs for UF patients in real-world practice settings 
using managed care claims data. METHODS: In this retrospective database study, 
women with a UF diagnosis between 15 and 51 years of age were selected between 
2000 and 2006. An index date was deﬁned as the date of ﬁrst observed UF diagnosis. 
All patients were required to have continuous plan enrollment 6 months pre- and 36 
months post-index date. Summary statistics for patient characteristics, probability of 
ﬁrst UF-related surgery, any repeat UF-related surgery, and total medical and phar-
macy costs (2007 US$) incurred 12 months post-index date were generated. RESULTS: 
A total of 109,595 patients met the study inclusion criteria. The mean age at UF 
diagnosis was 43 years and the mean Charlson score was 0.27. Patients with com-
mercial insurance accounted for 91% of the population, while 75% had an HMO 
or PPO plan. The probability of UF-related surgery was 30.2%, 35.0%, and 38.4% 
within the 12-month, 24-month, and 36-month follow-up periods, respectively. 
Among patients with a UF-related surgery during the 36 month follow-up period, 
79.6%, 7.3%, 3.3%, 13.0% had hysterectomy, myomectomy, UAE/UAO, and abla-
tion, respectively. Mean age at ﬁrst surgery (44 years) varied by surgery type with 
younger women more likely to undergo myomectomy. The rate of repeat surgery 
within one year of ﬁrst surgery ranged from 1.6% (hysterectomy) to 10.5% (ablation). 
The mean total cost for all UF patients was $9608, 12 months post-index date. 
CONCLUSIONS: A substantial proportion of patients undergo UF-related surgeries 
within one to three years of diagnosis, with hysterectomy being the most common 
surgery. UF-related surgeries present signiﬁcant clinical and economic implications 
that should be understood by private and public third party payers who bear the 
ﬁnancial burden of UF surgical care.
PIH11
THE BURDEN OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER 
(ADHD) ON PATIENTS HOSPITALIZED WITH A PRIMARY DIAGNOSIS 
OF OPPOSITIONAL DEFIANT DISORDER (ODD)
Meyers J1, Classi P2, Wietecha LA2, Candrilli S1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly and Company, Indianapolis, 
IN, USA
OBJECTIVES: To assess length of stay (LOS) and costs attributable to ADHD among 
adolescents hospitalized with a primary diagnosis of ODD. METHODS: Patients 
12–17 years old with a primary diagnosis of ODD (ICD-9-CM code 313.81) were 
selected from the 2000 to 2006 Health care Cost and Utilization Project Nationwide 
Inpatient Sample (HCUP-NIS). Patients with a diagnosis of ADHD (ICD-9-CM codes 
314.00 and 314.01) comprised the study cohort and patients without an ADHD 
diagnosis comprised the control cohort. Study measures included demographics, hos-
pital characteristics, admission source, discharge disposition, LOS, and costs. General-
ized linear models accounting for the HCUP-NIS survey design were undertaken to 
adjust LOS and cost estimates. RESULTS: A total of 7,404 and 18,039 patients met 
the inclusion criteria for the study and control cohorts, respectively. Patients in the 
study cohort were 6.8 months younger than patients in the control cohort (13.8 versus 
14.4 years). A higher percentage of patients in the study cohort were male (71.3% 
versus 45.2%) or had Medicaid (57.1% versus 48.6%) compared to the control 
cohort. In both cohorts, the ER was the most common admission source, approxi-
mately 90% of patients had their discharge disposition recorded as routine, and most 
patients were treated in urban, teaching, or large bedsize hospitals. The study cohort 
had longer LOS and higher costs versus the control cohort (mean [SE] 9.48 [0.89] 
days and $8241 [$1356] versus 7.90 [0.59] days and $6466 [$709]). Regression 
analyses found the study cohort had signiﬁcantly longer LOS and higher costs versus 
the control cohort (by 2.5 days and $1338). CONCLUSIONS: Patients hospitalized 
with a primary diagnosis of ODD and a secondary diagnosis of ADHD had signiﬁ-
cantly longer LOS and higher costs compared to patients with ODD but without 
ADHD. Clinicians and health care decision-makers should be aware of the impact 
ADHD has on inpatient stays among patients with ODD.
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DULOXETINE DOSING PATTERNS AND HEALTH CARE COSTS AMONG 
ELDERLY DIAGNOSED WITH FIBROMYALGIA
Wu N1, Chen SY1, Rao P2, Boulanger L1, Peng X3, Zhao Y3
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Abt Bio-Pharma Solutions, Inc, 
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OBJECTIVES: This study employed a retrospective cohort design to examine patterns 
of duloxetine utilization and health care costs among elderly ﬁbromyalgia patients. 
METHODS: Pharmacy and medical claims were analyzed for ﬁbromyalgia patients 
aged 65+ with Medicare supplemental insurance who initiated duloxetine in 2006. 
The index date was deﬁned as the dispense date of the ﬁrst duloxetine prescription 
ﬁlled, with no duloxetine coverage in the prior 90 days. Patients were required to have 
at least 30 supply days of duloxetine in the 12 months post-index period. Individuals 
with any diagnosis of diabetic peripheral neuropathic pain or depression during the 
12 months pre-index period were excluded. Five study cohorts were constructed based 
on the index dosage: <30 mg, 30 mg, 31–59 mg, 60 mg, and >60 mg. Patterns of dulox-
etine use including changes in dosage, average daily dose (ADD), adherence to dulox-
etine (medication possession ratio≥0.8 as high adherence) were examined across study 
cohorts. Regression models were performed to estimate the differences in health care 
costs. RESULTS: A total of 566 ﬁbromyalgia patients were included, with 41, 163, 
47, 294 and 21 in the <30 mg, 30 mg, 31–59 mg, 60 mg, and >60 mg cohorts, respec-
tively. A total of 31.4% of patients experienced any dosage changes (increased dosage: 
25.8%; decreased dosage: 15.7%). Among those who changed dosage, patients in the 
31–59 mg cohort had the shortest time to change (81 days), and patients in the <30 mg 
cohort had the longest (149 days) time. ADD trended upward as index dose increased. 
Compared with patients in the 60 mg cohort, those in the <30 mg and >60 mg cohorts 
were less likely to be adherent (odds ratios 0.40 and 0.30, respectively, both p < 0.05). 
Post-index total health care costs were similar across cohorts. CONCLUSIONS: 
Dosage changes occurred most quickly in ﬁbromyalgia patients with an index dose of 
31–59 mg of duloxetine. Duloxetine ADD and adherence differ by index dosage, while 
health care costs remain similar.
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HEALTH CARE UTILIZATION AND COSTS FOR THE TREATMENT OF 
HYPOACTIVE SEXUAL DESIRE DISORDER
Palmer L1, Johnson BH1, Foley D2
1Thomson Reuters, Washington, DC, USA, 2Boehringer-Ingelheim, Ridgeﬁeld, CT, USA
OBJECTIVES: Hypoactive sexual desire disorder (HSDD) is characterized by persis-
tent/ recurring deﬁciency of sexual fantasies or thoughts, and/or the absence of desire 
for sexual activity. Despite the potentially high prevalence of the condition, few studies 
have evaluated the cost of treating women with HSDD. The current study describes 
health care utilization and costs among women suffering from HSDD relative to 
women without evidence of female sexual dysfunction (FSD). METHODS: Women 
aged 18–64 with a diagnosis of HSDD (ICD-9-CM: 302.71) were identiﬁed using the 
Marketscan® Commercial Claims and Encounters Databases from Thomson Reuters. 
Women were identiﬁed between January 1, 1998-December 31, 2007 and were 
matched 1:3 to women without FSD (ICD-9-CM: 302.7x; 306.51) based on age, 
health plan type and months with medical/pharmacy beneﬁts. Utilization and costs 
were evaluated during the 12, 24 and 36- month periods following HSDD diagnosis. 
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RESULTS: A total fo 3,975 women with HSDD and 11,925 controls were identiﬁed 
for the 12-month follow-up period. Women with HSDD had signiﬁcantly fewer 
inpatient admissions (0.07 vs. 0.09) and more general outpatient medical (29.26 vs. 
19.13), behavioral health ofﬁce (1.82 vs. 0.71) and more radiology (3.10 vs. 2.30) 
visits in the 12-month follow-up period versus controls. Cost differences were also 
observed among women with HSDD relative to their controls—with greater costs for 
general outpatient medical ($3427), behavioral health ofﬁce ($197) and radiology 
($515) visits in the 12-month follow-up period among women with HSDD than for 
controls (general outpatient medical visits: $2334; behavioral health ofﬁce visits: $77; 
radiology visits: $377; all p < 0.001). Differences in utilization and costs persisted in 
the 24 and 36-month follow-up periods. CONCLUSIONS: Women with HSDD have 
higher ‘downstream’ costs than women without any sexual dysfunction. The develop-
ment of treatment modalities that effectively control HSDD symptoms may present 
an opportunity to better manage health care utilization and costs in this population.
PIH14
COST-EFFECTIVENESS OF A HIGHLY PURIFIED HUMAN MENOPAUSAL 
GONADOTROPIN (HP-HMG) VERSUS RECOMBINANT FOLLICLE-
STIMULATING HORMONE (RFSH) IN PATIENTS PARTICIPATING IN AN 
ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) PROGRAM
Vicente C1, Poon Y2, Piwko C1
1Pivina Consulting Inc., Thornhill, ON, Canada, 2Ferring Inc., North York, ON, Canada
OBJECTIVES: To determine the cost-effectiveness of HP-HMG (menotropin, 
MENOPUR®) compared to rFSH (follitropin alpha, GONAL-F®), in producing live 
births in the ovulatory patient participating in an ART Program. METHODS: A previ-
ously validated and published European Markov model was adapted to the Canadian 
setting to estimate the incremental cost per additional live birth gained for HP-HMG 
compared to rFSH, projected over three treatment cycles. These cycles included an 
initial fresh cycle then two additional cycles, as needed, of either fresh or cryoperserved 
embryos. Live birth rates were derived from a published meta-analysis comparing 
HP-HMG menotropin to rFSH follitropin alpha. Factors such as discontinuation, 
ooctye fertilization and pregnancy rates were derived from the published literature. 
All clinical outcomes were validated against published Canadian ART registry data 
and through clinical expert review. The analysis focused on direct medical costs only 
from the perspective of a provincial public health care system (Quebec). Cost data 
were obtained from a variety of sources including published references, provincial 
health care sources and expert opinion. All costs were reported as 2009 Canadian 
Dollars ($CAD). Given the short time-horizon discounting was not applied. Multiple 
sensitivity analyses were undertaken to test the robustness of the model to variations 
in key parameters including the cost and relative outcomes of comparators. RESULTS: 
The base case analysis indicates that HP-HMG results in a total cost per patient of 
$CAD 11,742 over 3 cycles compared to $CAD 13,202 for rFSH. Further, treatment 
with HP-HMG results in more live births than rFSH with 0.485 versus 0.421, respec-
tively. Thus, treatment with HP-HMG is dominant relative to rFSH (less costly and 
more effective). Results were robust over multiple sensitivity analyses. CONCLU-
SIONS: Treatment with HP-HMG (MENOPUR) is cost-effective compared to rFSH 
(GONAL-F), providing a greater number of live births at a lower cost to the public 
health care system.
PIH15
COST EFFECTIVENESS ANALYSIS OF FDA APPROVED ORAL 
EMERGENCY CONTRACEPTIVES
Patel HK, Patel J, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: Unintended pregnancies, a health problem with signiﬁcant economic 
burden on US could be avoided by use of FDA approved oral emergency contraceptives 
(ECPs) namely Plan B one-step (one pill regimen) and Next choice (two pill regimen). 
The objective of this study was to conduct a head-to-head comparison of these oral 
ECPs. METHODS: A cost effectiveness (CE) decision tree model was developed using 
data from published randomized controlled trails (effectiveness values) and primary 
data collection. Cost of each drug was obtained by taking an average of the price of 
drug from 5 large chain pharmacies. Outcomes considered were no pregnancy, birth, 
induced abortion, spontaneous abortion or ectopic pregnancy. Cost and probabilities 
of each outcome was derived from past literature and included only the direct costs. 
All adverse events with a probability of more than 5% and the direct cost associated 
with treating each of those adverse events were considered. These adverse events gener-
ally last for duration of one week, which was used to derive cost information for 
adverse events. The analysis involved only a onetime cost of taking an emergency 
contraceptive. Results were validated using one way and two way sensitivity analyses 
by varying the cost and effectiveness by a range of 25% each. RESULTS: The brand 
name drug Plan B one-step as opposed to the generic counterpart available, Next 
Choice, emerged as the cost effective option to avoid unintended pregnancy. The cost 
of treatment with Plan B one-step was $859 as opposed to $1075 for Next Choice. 
Two-way sensitivity analyses were robust and indicated that treatment with Plan B 
one-step completely dominated Next Choice. CONCLUSIONS: Plan B one-step; a one 
pill emergency contraceptive drug, with a higher retail price was found to be more 
cost effective than Next Choice.
PIH16
COST-EFFECTIVENESS ANALYSIS FOR TREATMENT OF SYMPTOMATIC 
UTERINE FIBROIDS AMONG PREMENOPAUSAL WOMEN SEEKING TO 
RETAIN UTERUS
Talbird SE1, Bell KF2, Graham JB1, Deal LS2, Mauskopf J1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Wyeth Research (a Pﬁzer 
Company), Collegeville, PA, USA
OBJECTIVES: To determine the cost-effectiveness of different treatment options and 
optimal number of treatments for symptomatic uterine ﬁbroids among premenopausal 
women who would prefer to retain uterus. METHODS: A Markov model with a 
1-year cycle length was developed. Women entered the model at diagnosis with 
symptomatic ﬁbroids and were followed to menopause or age 60 years, when all 
women were assumed to reach menopause. Treatment options included watchful 
waiting, myomectomy, and one-time, 6-month use of gonadotropin-releasing hormone 
(GnRH). In the model, women treated unsuccessfully or whose symptoms recurred 
could undergo up to three additional treatments or stop treatment at any point. Data 
on treatment efﬁcacy, quality-of-life, and medical costs (2007 US$) were from pub-
lished studies. For myomectomy, the probabilities of repeat procedures and of emer-
gency hysterectomy were from a large US claims database analysis. Age-speciﬁc rates 
for pregnancy and menopause were based on US data. Total costs and quality-adjusted 
life years (QALYs), discounted annually at 3%, were calculated for each treatment 
strategy for women diagnosed at different ages. Incremental cost-effectiveness ratios 
(ICERs) were calculated and an efﬁciency frontier was plotted. RESULTS: Base-case 
results for women diagnosed at age 20 years showed treatment strategies including 
GnRH were dominant compared with treatment strategies including myomectomy 
only and were cost-effective compared with watchful waiting (ICER range: $3789-
$7456 per QALY gained). Additional procedures for women whose symptoms 
recurred led to increased medical costs and QALYs, resulting in an incremental cost 
per QALY gained of $13,307, $15,433, and $17,555 for the second, third, and fourth 
myomectomy, respectively. Results were sensitive to age at diagnosis, number of treat-
ments, and the disutility associated with a woman losing her uterus via emergency 
hysterectomy. CONCLUSIONS: This model is the ﬁrst to assess the cost-effectiveness 
and optimal number of treatments speciﬁcally for a woman with ﬁbroids seeking to 
retain her uterus.
PIH17
COST-EFFECTIVENESS ANALYSIS OF FOUR EMBRYO TRANSFER 
STRATEGIES
You J1, Lok IH2
1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2The Chinese University of 
Hong Kong, Shatin, Hong Kong
OBJECTIVES: The objective of this study was to evaluate the cost and clinical out-
comes of single versus double embryo transfer using cleavage-stage or blastocyst-stage 
embryo in assisted reproduction. METHODS: Markov model was designed to simu-
late outcomes of: 1) single-(cleavage-stage) embryo transfer (SET); 2) double-embryo 
transfer (DET); 3) single-blastocyst transfer (SBT); and 4) double-blastocyst transfer 
(DBT). Model inputs were estimated from literature and cost analysis was conducted 
from health care provider’s perspective. RESULTS: The base-case analysis showed 
that DBT was the most costly (US$5173) and effective strategy (birth rate = 0.311) 
in fresh cycle. The cumulative cost and birth rate of SET were the highest in all cycles. 
Monte Carlo 10,000 simulations showed that the probability of DBT to be cost-
effective in fresh cycle was the highest when willingness-to-pay (WTP) per live birth 
was ≥US$85,000. In all cycles, the probability of SET to be cost-effective was the 
highest when WTP was ≥US$50,000. CONCLUSIONS: CONCLUSIONS DBT 
appears to be the most costly and most effective strategy in fresh cycle whereas SET 
seems to have the highest cumulative cost and live birth rate.
PIH18
ANALYSIS OF NECROTIZING ENTEROCOLITIS COSTS AMONG 
EXTREMELY PRETERM INFANTS FED EXCLUSIVELY HUMAN-MILK 
BASED DIET VS. HUMAN-MILK FORTIFIED WITH BOVINE-MILK BASED 
SUPPLEMENTS
Ganapathy V1, Hay JW1, Kim J2
1University of Southern California, Los Angeles, CA, USA, 2University of California San 
Diego, San Diego, CA, USA
OBJECTIVES: To estimate the incremental costs of necrotizing enterocolitis (NEC) 
among extremely preterm infants (GA < 28 weeks) and to evaluate the cost-effective-
ness of an exclusively human-milk based diet (fortiﬁed with Prolacta + HMFTM) vis-
à-vis human-milk fortiﬁed with a bovine-milk based supplement in the prevention of 
NEC. METHODS: California OSHPD 2007 hospital discharges database was used 
to estimate the incremental costs of NEC and surgical NEC among all preterm infants. 
Costs were adjusted for confounding by demographics, gestation age, mortality and 
comorbidities. Expected medical costs of NEC among extremely preterm infants fed 
either exclusively human-milk based diet or human-milk fortiﬁed with bovine-milk 
based fortiﬁer were calculated based on ﬁndings from a randomized controlled trial 
comparing neonatal outcomes of extremely preterm infants fed either of these diets. 
RESULTS: The adjusted incremental costs of NEC and surgical NEC among extremely 
preterm infants in 2009 US$ were 69,185 and $198,490 respectively per infant (p < 
0.0001). Expected medical costs of NEC were higher among infants fed human-milk 
fortiﬁed with bovine-milk based supplement resulting in net savings of $16,875 per 
infant for infants fed exclusively human-milk based diet (p < 0.0001). The societal 
costs savings for the US population of premature infants is estimated to be US$ 
